Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 23, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq:PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported on December 23, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 52,560 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 65,701 shares of Pyxis Oncology’s common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of December 23, 2022, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at globenewswire.com